1. Lee-Jones, C., et al., Fear of cancer recurrence – a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology, 1997, 6(2): 95–105.
2. Lederer, S.E., Dark victory: cancer and popular Hollywood film. Bull Hist Med, 2007, 81(1): 94–115.
3. Sporn, M.B., The war on cancer: a review. Ann N Y Acad Sci, 1997, 833: 137–46.
4. Reisfield, G.M. and G.R. Wilson, Use of metaphor in the discourse on cancer. J Clin Oncol, 2004, 22(19): 4024–27.
5. Williams Camus, J., Metaphors of cancer in scientific popularization articles in the British press. Discourse Studies, 2009, 11: 465–95.
6. van’t Spijker, A., R.W. Trijsburg, and H.J. Duivenvoorden, Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med, 1997, 59(3): 280–93.
7. Australian Health Technology Advisory Committee, Prostate cancer screening. 1996, Canberra: AGPS.
8. Cancer Council Australia, National cancer prevention policy 2007–09. 2007, Sydney: Cancer Council Australia.
9. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice 7th edition. Accessed from: www.racgp.org.au/redbook/9-7 [Cited 30 Aug 2010].
10. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. Available from: www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer?siterea=PED[Cited 30 Aug 2010]. 120
11. BC Cancer Agency. Prostate cancer. 2003. Accessed from: www.bccancer.bc.ca/PPI/Screening/Prostate.htm [Cited 30 Aug 2010].
12. UK National Screening Committee. The UK NSC policy on prostate cancer screening/PSA testing in men over the age of 50. Available from: www.screening.nhs.uk/prostatecancer [Cited 30 Aug 2010].
13. US Preventive Services Task Force, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2008, 149(3): 185–91.
14. Prostate Cancer Research Foundation of Australia. PSA/DRE testing for early detection of prostate cancer. 2006. Available from: www.prostate.org.au/articleLive/attachments/1/PCFA PSA DRE Policy Statement 270706.pdf [Cited 30 Aug 2010].
15. Frankel, S., et al., Screening for prostate cancer. Lancet Oncol, 2003, 361(9363): 1122–28.
16. Holden, C.A., et al., Men in Australia Telephone Survey (MATeS): predictors of men’s help-seeking behaviour for reproductive health disorders. Med J Aust, 2006, 185(8): 418–22.
17. Overton P. Secret men’s business. 60 Minutes, 15 Aug 2005. Available from: sixtyminutes.ninemsn.com.au/stories/peteroverton/259324/secret-mens-business [Cited 30 Aug 2010].
18. Schroder, F.H., et al., Screening and prostate-cancer mortality in a randomized European study, [see comment]. New England Journal of Medicine, 2009, 360(13): 1320–28.
19. Margo, J., Cancer test: an expert refusal. Australian Financial Review, 6 Feb 2003, pp. 59–60.
20. Commonwealth of Australia, Parliamentary Debates, House of Representatives 5560-15563 (Jim Lloyd) and Editors. 21 June 2003. 121
21. Anon, The prostate and the apostate (Editorial). Sydney Morning Herald, 7 March 2003.
22. Coates, A., Letter. Sydney Morning Herald, 10 March 2003.
23. Livingston, P., M. Wakefield, and J.M. Elwood, Community attitudes towards the early detection of cancer in Victoria, Australia. Aust N Z J Public Health, 2007, 31(1): 26–29.
24. Schwartz, L.M., et al., Enthusiasm for cancer screening in the United States. JAMA, 2004, 291(1): 71–78.
25. Gattellari, M. and J.E. Ward, Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial. J Med Screen, 2003, 10(1): 27–39.
26. Flood, A.B., et al., The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med, 1996, 11(6): 342–49.
27. Volk, R.J., A.R. Cass, and S.J. Spann, A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med, 1999, 8(4): 333–40.
28. Wolf, A.M., J.F. Nasser, and J.B. Schorling, The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med, 1996, 156(12): 1333–36.
29. Davison, B.J., et al., Information and patient participation in screening for prostate cancer. Patient Educ Couns, 1999, 37(3): 255–63.
30. Ferriman, A., Advocates of PSA testing campaign to silence critics. BMJ, 2002, 324(7332): 255.
31. Yamey, G. and M. Wilkes, The PSA storm: questioning cancer screening can be a risky business in America. BMJ, 2002, 324: 431.
32. Movember Australia. Men’s health. Available from: au.movemberfoundation.com/mens-health/ [Cited 30 Aug 2010].
33. Neal, D.E., PSA testing for prostate cancer improves survival-but can we do better? Lancet Oncol, 2010, 11(8): 702–03. 122
34. Hugosson, J., et al., Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol, 2010, 11(8): 725–32.
35. Waterstreet, C., Movember is for jerks. Sun Herald, 21 Nov 2009.
36. Hoffman, R.M., et al., Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS Study). Arch Intern Med, 2009, 169(17): 1611–18.
37. Collins, M.M., et al., How common is prostatitis? A national survey of physician visits. J Urol, 1998, 159(4): 1224–28.
38. Krieger, J.N., L. Nyberg, Jr., and J.C. Nickel, NIH consensus definition and classification of prostatitis. JAMA, 1999, 282(3): 236–37.
39. Dimitrakov, J.D., et al., Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach. Urology, 2006, 67(5): 881–88.
40. Verhamme, K.M., et al., Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – the Triumph project. Eur Urol, 2002, 42(4): 323–28.
41. Davies, L. and H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 2006, 295(18): 2164–67.
42. Breslow, N., et al., Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer, 1977, 20(5): 680–88.
43. Yin, M., et al., Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol, 2008, 179(3): 892–95; discussion 895.
44. Australian Institute of Health and Welfare, Cancer data online. Available from: www.aihw.gov.au:80/cancer/ [Cited 30 Aug 2010].
45. Australian Institute of Health and Welfare, Chronic diseases mortality. Available from: www.aihw.gov.au/cdarf/data_pages/mortality/index.cfm [Cited 30 Aug 2010].
46. Mackenzie, R., et al., The newsworthiness of cancer in Australian television news. Med J Aust, 2008, 189(3): 155–58. 123
47. MacKenzie, R., et al., “The news is [not] all good”: misrepresentations and inaccuracies in Australian news media reports on prostate cancer screening [see comment]. Medical Journal of Australia, 2007, 187(9): 507–10.
48. MacKenzie, R., et al., ‘A matter of faith, not science’: analysis of media coverage of prostate cancer screening in Australian news media 2003–2006. J R Soc Med, 2007, 100(11): 513–21.
49. Prostate Cancer Foundation of Australia, Prostate cancer statistics. Available from: www.prostate.org.au/articleLive/pages/Prostate-Cancer-Statistics.html [Cited 30 Aug 2010].
50. Australian Institute of Health and Welfare. Cancer in Australia: an overview, 2008. Available from: www.aihw.gov.au/publications/can/ca08/ca08.pdf [Cited 30 Aug 2010].
51. AAP, Experts aim to beat prostate cancer fear. Sydney Morning Herald, 12 July 2010.
52. Roehl, K.A., et al., Characteristics of patients with familial versus sporadic prostate cancer. J Urol, 2006, 176(6 Pt 1): 2438–42; discussion 2442.
53. Bratt, O., What should a urologist know about hereditary predisposition to prostate cancer? BJU Int, 2007, 99(4): 743–47; discussion 747–48.
54. Wakefield, C.E., et al., Issues faced by unaffected men with a family history of prostate cancer: a multidisciplinary overview. J Urol, 2008, 180(1): 38–46; discussion 46.
55. Zeegers, M., A. Jellema, and H. Ostrer, Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma. Cancer, 2003, 97(8): 1894–1903.
56. Edwards, S.M. and R.A. Eeles, Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet, 2004, 129C(1): 65–73.
57. Merrill, R.M. and J.S. Bird, Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control, 2002, 13(5): 435–43.
58. Lin, D.W., M. Porter, and B. Montgomery, Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer, 2009, 115(13): 2863–71. 124
59. Key, T.J., et al., The effect of diet on risk of cancer. Lancet Oncol, 2002, 360(9336): 861–68.
60. Cowan, R., et al., The beliefs, and reported and intended behaviors of unaffected men in response to their family history of prostate cancer. Genet Med, 2008, 10(6): 430–38.
61. Muller, D.C., et al., Dietary patterns and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 2009, 18(11): 3126–29.
62. Boehm, K., et al., Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev, 2009, 3: CD005004.
63. Etminan, M., B. Takkouche, and F. Caamano-Isorna, The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev, 2004, 13(3): 340–45.
64. Lippman, S.M., et al., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2009, 301(1): 39–51.
65. Thompson, I.M., et al., The influence of finasteride on the development of prostate cancer. N Engl J Med, 2003, 349(3): 215–24.
66. Lucia, M.S., et al., Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa), 2008, 1(3): 167–73.
67. Pinsky, P., H. Parnes, and L. Ford, Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila Pa), 2008, 1(3): 182–86.
68. Leitzmann, M.F., et al., Ejaculation frequency and subsequent risk of prostate cancer. JAMA, 2004, 291(13): 1578–86.
69. Dimitropoulou, P., et al., Sexual activity and prostate cancer risk in men diagnosed at a younger age. BJU Int, 2009, 103(2): 178–85.
70. Lee, I.M., et al., Does physical activity play a role in the prevention of prostate cancer? Epidemiol Rev, 2001, 23(1): 132–37. 125
71. Harris, R. and L. KN., Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, 137(11): 915–17.
72. Thompson, I., et al., Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med, 2004, 350(22): 2239–46.
73. Oesterling, J.E., et al., Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 1993, 270(7): 860–64.
74. Albin, R.J., The great prostate mistake. New York Times, 9 March 2010.
75. Adapted from: BUPA. Transrectal ultrasound-guided prostate biopsy. 2008. Available from: hcd2.bupa.co.uk/fact_sheets/html/transrectal_prostate_biopsy.html [Cited 30 Aug 2010].
76. Rietbergen, J.B., et al., Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology, 1997, 49(6): 875–80.
77. Brullet, E., et al., Massive rectal bleeding following transrectal ultrasoundguided prostate biopsy. Endoscopy, 2000, 32(10): 792–95.
78. Borer, A., et al., Fatal Clostridium sordellii ischio-rectal abscess with septicaemia complicating ultrasound-guided transrectal prostate biopsy. J Infect, 1999, 38(2): 128–29.
79. Fall K, et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med, Dec 2009. Available from: www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000197 [Cited 30 Aug 2010].
80. Bill-Axelson, A., et al., Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol, 2010, 57(3): p. 390–95.
81. Adapted from: US Agency for Healthcare Research and Quality. Treating cancer: a guide for men with localized prostate cancer. July 2008. Accessed 126from: www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guide-sreviews-and-reports/?pageaction=displayproduct&productID=98 [Cited 30 Aug 2010].
82. Bill-Axelson, A., et al., Radical prostatectomy versus watchful waiting in early prostate cancer. [see comment]. New England Journal of Medicine, 2005, 352(19): 1977–84.
83. Bill-Axelson, A., et al., Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst, 2008, 100(16): 1144–54.
84. Adapted from: Macmillan Cancer Support. Radiotherapy for early prostate cancer, 2007. Available from: www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Treatmentforearlyprostatecancer/Radiotherapy.aspx [Cited 30 Aug 2010].
85. Adapted from: Roswell Park Cancer Institute. Prostate cancer. Available from: www.prostatepros.com/treatment-options/hormonal-therapy-adt-prostate-cancer [Cited 30 Aug 2010].
86. Thompson, I., et al., Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol, 2007, 177(6): 2106–31.
87. Wilt, T.J., et al., Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med, 2008, 148(6): 435–48.
88. Ellison, L.M., J.A. Heaney, and J.D. Birkmeyer, The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol, 2000, 163(3): 867–69.
89. Yao, S.L. and G. Lu-Yao, Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst, 1999, 91(22): 1950–56.
90. Begg, C.B., et al., Variations in morbidity after radical prostatectomy. N Engl J Med, 2002, 346(15): 1138–44.
91. Hunter, K.F., et al., Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev, 2004, 2: CD001843. 127
92. Lin, K., et al., Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med, 2008, 149(3): 192–99.
93. Lin K, et al., Benefits and harms of prostate-specific cancer screening: an evidence update for the US Preventive Services Task Force. In Evidence Synthesis, No. 63. AHRQ Publication No. 08–05121-EF-1. August 2008, Rockville, Maryland: Agency for Healthcare Research and Quality.
94. Australlian Broadcasting Corporation. Robots and surgery. 26 Feb 2009. Available from: www.abc.net.au/rn/futuretense/stories/2009/2500206.htm [Cited 30 Aug 2010].
95. Myprostate.com.au. Surgery – robotic – da Vinci. Available from: myprostate.com.au/surgery_da_vinci.htm [Cited 30 Aug 2010].
96. Masters, C., Cutting edge surgery – da Vinci robot’s mission is to eliminate cancer. Daily Telegraph. 27 May 2006.
97. da Vinci Prostatecomy. Available from: www.davinciprostatectomy.com/index.aspx [Cited 9 Dec 2009].
98. Kooner, R., Robotic prostate surgery. St Vincent’s Clinic: Sydney.
99. Australian Institute for Robotic Surgery. Available from: www.epworth.org.au/Main-Site/Our-Services/Centres-of-Excellence/Australian-Institute-for-Robotic-Surgery.aspx [Cited 30 Aug 2010].
100. Hu, J., et al., Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA, 2009, 302(14): 1557–64.
101. Doumerc, N., et al., Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years. BJU Int. 106(3): 378-84.
102. Smith, D.P., et al., Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ, 2009, 339: b4817.
103. Wilson, G.M.G. and G. Jungner, Principles and practice of screening for disease. Public Health Papers, 1968, 34: 1–163. 128
104. Keirns, C.C. and S.D. Goold, Patient-centered care and preference-sensitive decision making. JAMA, 2009, 302(16): 1805–06.
105. Andriole, G.L., et al., Mortality results from a randomized prostate-cancer screening trial [see comment]. New England Journal of Medicine, 2009, 360(13): 1310–19.
106. Gøtzsche, P.C. and M. Nielsen, Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews, 2009, 4: CD001877.
107. Kolata G. Prostate test found to save few lives. New York Times, 18 Mar 2009. Available from: www.nytimes.com/2009/03/19/health/19cancer.html?_r=2&em&source=cmailer [Cited 30 Aug 2010].
108. Etzioni, R., et al., Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst, 2002, 94(13): 981–90.
109. Medd, J.C., et al., Measuring men’s opinions of prostate needle biopsy. ANZ J Surg, 2005. 75(8): 662–64.
110. Urological Sociery of Australia and New Zealand. Urological Society of Australia and New Zealand PSA testing policy 2009. Available from: www.usanz.org.au/uploads/29168/ufiles/USANZ_2009_PSA_Testing_Policy_Final1.pdf [Cited 30 Aug 2010].
111. Jorgensen, K.J. and P.C. Gotzsche, Breast screening: fundamental errors in estimate of lives saved by screening. BMJ, 2009, 339: b3359.
112. Morrell, S., et al., Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control, 2010, 21(2): 275–82.
113. Welch, H.G., Overdiagnosis and mammography screening. BMJ, 2009, 339: b1425.
114. Young, J.M. and J.E. Ward, Declining rates of smoking among medical practitioners. Med J Aust, 1997, 167(4): 232. 129
115. Livingston, P., et al., Knowledge, attitudes and experience associated with testing for prostate cancer: a comparison between male doctors and men in the community. Intern Med J, 2002, 32(5–6): 215–23.
116. Australian Institute of Health and Welfare. Cancer in Australia. 2005, 92, Table 46. Available from: www.aihw.gov.au/publications/index.cfm/title/10083 [Cited 30 Aug 2010].
117. Us Too. Prostate Cancer Education and Support. Corporate supporters. Available from: www.ustoo.org/Corporate_Sponsors.asp [Cited 9 Dec 2009].
118. Lenzer, J., Lay campaigners for prostate screening are funded by industry. BMJ, 2003, 326(7391): 680.
130